Drug Type Small molecule drug |
Synonyms- |
Target |
Action inhibitors |
Mechanism KRAS G12D inhibitors(GTPase KRas G12D inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC31H34F5N7O |
InChIKeyKIYCQGPXMSRTAC-MKHLDVKISA-N |
CAS Registry3077321-55-9 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Colorectal Cancer | Preclinical | United States | 16 May 2025 | |
| Lung Cancer | Preclinical | United States | 16 May 2025 | |
| Pancreatic Cancer | Preclinical | United States | 16 May 2025 |





